PDF(1173 KB)
PDF(1173 KB)
PDF(1173 KB)
原癌基因Fra-1在肾母细胞瘤患儿血液中的表达及其意义
Expression of the Fra-1 gene in the peripheral blood of children with Wilms tumor
目的 探讨原癌基因Fra-1在肾母细胞瘤患儿血液中的表达及其意义。方法 选取2012年12月至2018年1月病理明确诊断为肾母细胞瘤的患儿作为病例组（n=50），健康体检儿童作为对照组（n=40）；获得随访的45例患儿中，将持续缓解患儿纳入理想疗效组（n=33），复发、转移或死亡患儿纳入疗效不佳组（n=12）。采集所有研究对象外周血，通过实时荧光定量PCR检测Fra-1 mRNA表达水平。结果 肾母细胞瘤患儿血液中Fra-1 mRNA相对表达量明显高于对照组（P < 0.05）。Fra-1 mRNA的表达水平在肾母细胞瘤是否远处转移及TNM分期间比较差异有统计学意义（P < 0.05），而在患儿的性别、年龄、肿瘤直径、肿瘤位置及不同甲胎蛋白（AFP）水平间比较差异均无统计学意义（P > 0.05）。理想疗效组Fra-1 mRNA相对表达量低于疗效不佳组（P < 0.05）。结论 Fra-1可能参与肾母细胞瘤的形成，并在其发展、侵袭及转移中起一定作用，但具体机制仍有待深入研究。
Objective To study the expression of the Fra-1 gene in the peripheral blood of children with Wilms tumor and its clinical significance. Methods Fifty children pathologically diagnosed with Wilms tumor between December 2012 and January 2018 were enrolled as the case group, and 40 healthy children for physical examination were selected as the control group. Among the 45 children with Wilms tumor who were followed up, the children with continuous remission were included in the ideal efficacy group (n=33), and those with recurrence, metastasis or death were included in the poor efficacy group (n=12). Peripheral blood samples were collected from all subjects. Quantitative real-time PCR was used to measure the mRNA expression of Fra-1. Results The case group had significantly higher mRNA expression of Fra-1 in peripheral blood than the control group (P < 0.05). In the case group, Fra-1 mRNA expression was significantly different between the individuals with and without distant metastasis and those with different TNM stages (P < 0.05), but was not significantly different between the individuals with different sexes, ages, tumor diabetes, tumor locations and alpha-fetoprotein levels (P > 0.05). The mRNA expression of Fra-1 was significantly lower in the ideal efficacy group than in the poor efficacy group (P < 0.05). Conclusions Fra-1 may be involved in the development of Wilms tumor and plays a certain role in its development, invasion and metastasis, but the mechanism remains to be further studied.
Wilms tumor / Fra-1 / Prognosis / Child
[1] Friedman AD. Wilms tumor[J]. Pediatr Rev, 2013, 34(7):328-330.
[2] Davenport KP, Blanco FC, Sandler AD. Pediatric malignancies:neuroblastoma, Wilm's tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma[J]. Surg Clin North Am, 2012, 92(3):745-767.
[3] Verschuur AC, Vujanic GM, Van TH, et al. Stromal and epithelial predominant Wilms tumours have an excellent outcome:the SIOP 9301 experience[J]. Pediatr Blood Cancer, 2010, 55(2):233-238.
[4] Gleason JM, Lorenzo AJ, Bowlin PR, et al. Innovations in the management of Wilms' tumor[J]. Ther Adv Urol, 2014, 6(4):165-176.
[5] Zhong G, Chen X, Fang X, et al. Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway[J]. Oncol Rep, 2016, 35(1):447-453.
[6] Iskit S, Schlicker A, Wessels L, et al. Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts diseasefree survival[J]. Oncotarget, 2015, 6(41):43146-43161.
[7] Oliveira-Ferrer L, Kürschner M, Labitzky V, et al. Prognostic impact oftranscription factor Fra-1 in ER-positive breast cancer:contribution to a metastatic phenotype through modulation of tumor cell adhesive properties[J]. J Cancer Res Clin Oncol, 2015, 141(10):1715-1726.
[8] Hasselblatt P, Gresh L, Kudo H, et al. The role of the transcription factor AP-1 in colitis-associated and β-catenindependent intestinal tumorigenesis in mice[J]. Oncogene, 2008, 27:6102-6109.
[9] Kent LN, Rumi MAK, Kubota K, et al. FOSL1 is integral to establishing the maternal-fetal interface[J]. Mol Cell Biol, 2011, 31(23):4801-4813.
[10] Lee BK, Uprety N, Jang YJ, et al. Fosl1 overexpression directly activates trophoblast-specific gene expression programs in embryonic stem cells[J]. Stem Cell Res, 2018, 26:95-102.
[11] Desmet CJ, Gallenne T, Prieur A, et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis[J]. Proc Natl Acad Sci U S A, 2013, 110(13):5139-5144.
[12] Sayan AE, Stanford R, Vickery R, et al. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL[J]. Oncogene, 2012, 31(12):1493-1503.
[13] Kimura R, Ishikawa C, Rokkaku T, et al. Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosaromac cells[J]. Biochim Biophys Acta, 2011, 1813(8):1543-1553.
[14] Zhang Q, Kleeberger SR, Reddy SP. DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung[J]. Am J Physiol Lung Cell Mol Physiol, 2004, 286(2):427-436.
[15] Tam WL, Lu H, Buikhuisen J, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells[J]. Cancer Cell, 2013, 24(3):347-364.
[16] Logullo AF, Nonogaki S, Pasini FS, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma[J]. Histopathology, 2011, 58(4):617-625.
[17] Usui A, Hoshino I, Akutsu Y, et al. The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma[J]. Cancer, 2012, 118(13):3387-3396.
[18] Wu J, Wu G, Lv L, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1[J]. Carcinogenesis, 2012, 33(3):519-528.
[19] Zhong G, Chen X, Fang X, et al. Fra-1 is upregulated in lung cancer tissues and inhibits the apoptosis of lung cancer cells by the P53 signaling pathway[J]. Oncol Rep, 2016, 35(1):447-453.
[20] Verde P, Casalino LF, Yaniv M, et al. Deciphering AP-1 function in tumorigenesis:fra-ternizing on target promoters[J]. Cell Cycle, 2007, 6(21):2633-2639.
